In Business 32 Years - Since 1980
THE CURRENT TIME at LC Labs is:
|
|
||||||
In Business 32 Years - Since 1980 |
THE CURRENT TIME at LC Labs is: |
|||||
[Capecitabin] [Capecitibine] [Capecytabine] [Capiibine] [Captabin] [Caxeta] [Ro 09-1978] [Xabine] [Xeloda]
|
 |
 |
|
Size |
US $ |
€ |
£ |
¥ |
|
||
|
1 g |
46 |
35 |
29 |
3500 |
| ||
|
2 g |
84 |
64 |
53 |
6400 |
| ||
|
5 g |
198 |
150 |
125 |
15200 |
| ||
|
10 g |
345 |
262 |
218 |
26400 |
| ||
|
25 g |
785 |
596 |
496 |
60200 |
| ||
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
| Compare Quality and Prices — LC Labs vs. Other Suppliers |
|---|
M.W. 359.35
C15H22FN3O6
[154361-50-9]
M.I. 14: 1754
Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; soluble in ethanol at 12.5 mg/mL with slight warming; soluble in water at 2 mg/mL with slight warming; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A
Find and View a Certificate of Analysis for this product
View the MSDS for this product
Capecitabine is a pre-prodrug of 5-fluorouracil (5-FU). After oral uptake, capecitabine is first metabolized to 5'-deoxy-5-fluorocytidine (5'-DFCR), which happens mainly in the liver by carboxyl-esterase. The metabolite is converted to 5'-deoxy-5-fluoro-uridine (5'-DFUR) by cytidine deaminase in liver and tumor tissue. Then 5'-DFUR is converted to 5-FU intracellularly by thymidine phosphorylase, which is often expressed in tumor tissue. Miwa, M., et al. "Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue." Eur. J. Cancer 34: 1274-1281 (1998).
Capecitabine inhibits tumor growth by incorporation of 5-FU into RNA and DNA and inhibition of thymidylate synthase. Schellens, J.H. "Capecitabine." Oncologist 12: 152-155 (2007).
Capecitabine is the active ingredient in the drug sold under the trade name Xeloda®. This drug has been approved in at least one country for use in patients with metastatic breast and colorectal cancers. NOTE: The capecitabine product sold by LC Laboratories is NOT Xeloda®, and is NOT for human use.
Other CAS numbers previously assigned to capecitabine, 158798-73-3 and 958887-39-3, have been deleted by CAS and are no longer in use.
Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use./b>.
This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
Not available in some countries; not available to some institutions; not available for some uses.
Our products are for laboratory research only and are sold only to qualified research institutions, not to individuals or patients nor for veterinary use.
